Published in Clin Pharmacol Ther on August 01, 1979
Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol (1986) 0.84
Stereoselective ring oxidation of propranolol in man. Br J Clin Pharmacol (1984) 0.82
Early kinetics of intravenous propranolol. Br J Clin Pharmacol (1982) 0.77
Clinical review of histamine2 receptor antagonists. Arch Intern Med (1990) 3.68
Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy. Arch Intern Med (1999) 2.05
The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther (1978) 1.51
THE EFFECTS OF AUTONOMIC NERVOUS SYSTEM INHIBITION ON THE CIRCULATORY RESPONSE TO MUSCULAR EXERCISE. J Clin Invest (1962) 1.41
Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther (1986) 1.31
The effects of injected norepinephrine and sympathetic nerve stimulation in hypothyroid and hyperthyroid dogs. J Pharmacol Exp Ther (1965) 1.29
Postprandial alterations in hemodynamics and blood pressure in normal subjects. Am J Cardiol (1986) 1.25
Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol (1999) 1.25
GLC determination of propranolol, other beta-blocking drugs, and metabolites in biological fluids and tissues. J Pharm Sci (1974) 1.22
Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol (2001) 1.21
Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol (1998) 1.18
Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther (1972) 1.17
Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1. J Pharmacol Exp Ther (2000) 1.14
Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos (1996) 1.11
Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol (1998) 1.10
Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther (1979) 1.10
Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res (2001) 1.06
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos (1998) 1.02
Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther (2000) 1.01
Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin. Clin Pharmacol Ther (1983) 1.01
4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther (1980) 1.00
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation. Pharm Res (2001) 1.00
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol (1993) 1.00
Methylation protects dietary flavonoids from rapid hepatic metabolism. Xenobiotica (2006) 0.99
Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol (2002) 0.98
Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites. Clin Pharmacol Ther (1981) 0.98
Calcium antagonists and mortality. Another case of the need for clinical judgment. Arch Intern Med (1995) 0.97
Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica (1999) 0.97
Acetylation of spermidine and spermine by rat liver and kidney chromatin. Arch Biochem Biophys (1977) 0.95
Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism. J Pharm Pharmacol (1999) 0.95
Stereoselective sulphate conjugation of fenoterol by human phenolsulphotransferases. Xenobiotica (1997) 0.94
Effect of methyldopa on plasma renin activity in man. Circ Res (1969) 0.93
Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr (2000) 0.93
Taxol metabolism and disposition in cancer patients. Drug Metab Dispos (1995) 0.93
Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol (1993) 0.93
Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res (2000) 0.93
Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol (1983) 0.92
Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos (1985) 0.92
Reversal of sympathetic nerve blockade: a comparison of dopa, dopamine, and norepinephrine with their alpha-methylated analogues. J Pharmacol Exp Ther (1965) 0.92
Identification of the unusual polyamines 3,3'-diaminodipropylamine and N,N'-bis(3-aminoproply)-1,3-propanediamine in the white shrimp Penaeus setiferus. Biochem Biophys Res Commun (1977) 0.91
Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol (2000) 0.90
Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Br J Clin Pharmacol (1996) 0.90
Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther (1984) 0.90
S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes. J Pharm Pharmacol (2005) 0.89
Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol (1996) 0.89
Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol (1998) 0.88
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos (2000) 0.88
Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther (1985) 0.88
Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol (1995) 0.88
Hep G2 cell line as a human model for sulphate conjugation of drugs. Xenobiotica (1992) 0.87
Carbon dioxide is the major metabolite of quercetin in humans. J Nutr (2001) 0.87
Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique. Res Commun Chem Pathol Pharmacol (1979) 0.87
Transport of genistein-7-glucoside by human intestinal CACO-2 cells: potential role for MRP2. Res Commun Mol Pathol Pharmacol (1999) 0.87
Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. J Pharmacol Exp Ther (1983) 0.86
Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Carcinogenesis (1998) 0.86
Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med (1993) 0.86